Photo by nci from unsplash
The CDK4/6 inhibitor abemaciclib is a mainstay of treatment for hormone receptor–positive breast cancer. However, increased venous thromboembolism (VTE) rates in multiple clinical trials resulted in a black‐box warning for… Click to show full abstract
The CDK4/6 inhibitor abemaciclib is a mainstay of treatment for hormone receptor–positive breast cancer. However, increased venous thromboembolism (VTE) rates in multiple clinical trials resulted in a black‐box warning for this agent. Thrombosis rates in unselected real‐world populations receiving abemaciclib remain ill defined.
Keywords:
cancer venous;
breast cancer;
venous arterial;
thrombosis;
cancer
Journal Title: Cancer
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!